Arctic Bioscience AS
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as int… Read more
Arctic Bioscience AS (ABS) - Total Liabilities
Latest total liabilities as of June 2025: Nkr95.05 Million NOK
Based on the latest financial reports, Arctic Bioscience AS (ABS) has total liabilities worth Nkr95.05 Million NOK as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Arctic Bioscience AS - Total Liabilities Trend (2018–2024)
This chart illustrates how Arctic Bioscience AS's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Arctic Bioscience AS Competitors by Total Liabilities
The table below lists competitors of Arctic Bioscience AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Exploits Discovery Corp
OTCQX:NFLDF
|
USA | $320.26K |
|
Silver Touch Technologies Limited
NSE:SILVERTUC
|
India | ₹1.34 Billion |
|
Nanotech Indonesia Global Tbk PT
JK:NANO
|
Indonesia | Rp42.12 Billion |
|
Charwood Energy SA
PA:ALCWE
|
France | €7.36 Million |
|
Panamax AG
F:ICP
|
Germany | €365.14K |
|
BAB Inc
OTCQB:BABB
|
USA | $1.45 Million |
|
Genetic Technologies Ltd
NASDAQ:GENE
|
USA | $4.36 Million |
|
Ladangbaja Murni PT Tbk
JK:LABA
|
Indonesia | Rp31.52 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Arctic Bioscience AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arctic Bioscience AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arctic Bioscience AS (2018–2024)
The table below shows the annual total liabilities of Arctic Bioscience AS from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Nkr69.01 Million | +65.51% |
| 2023-12-31 | Nkr41.69 Million | +3.15% |
| 2022-12-31 | Nkr40.42 Million | +93.22% |
| 2021-12-31 | Nkr20.92 Million | -28.50% |
| 2020-12-31 | Nkr29.26 Million | +57.56% |
| 2019-12-31 | Nkr18.57 Million | -21.03% |
| 2018-12-31 | Nkr23.52 Million | -- |